Fjarde Ap Fonden Gilead Sciences, Inc. Transaction History

Fjarde Ap Fonden

$9.8 Billion
Q3 2024

A detailed history of Fjarde Ap Fonden transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Fjarde Ap Fonden holds 297,963 shares of GILD stock, worth $27.6 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares

297,963

Previous 350,363 14.96%

Holding current value

$27.6 Million

Previous $25.7 Million 2.66%

% of portfolio

0.25%

Previous 0.28%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$66.59 - $83.99 $3.49 Million - $4.4 Million	-52,400 Reduced 14.96%	297,963 $25 Million
Q1 2024 Apr 25, 2024	BUY	$71.58 - $87.29 $1.02 Million - $1.25 Million	14,300 Added 4.26%	350,363 $25.7 Million
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $1.79 Million - $2.03 Million	-24,400 Reduced 6.77%	336,063 $27.2 Million
Q3 2023 Oct 23, 2023	SELL	$73.94 - $80.67 $354,912 - $387,216	-4,800 Reduced 1.31%	360,463 $27 Million
Q2 2023 Aug 02, 2023	SELL	$76.01 - $86.7 $653,686 - $745,620	-8,600 Reduced 2.3%	365,263 $28.2 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $1.44 Million - $1.64 Million	18,600 Added 5.24%	373,863 $31 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $1.64 Million - $2.35 Million	-26,290 Reduced 6.89%	355,263 $30.5 Million
Q2 2022 Aug 11, 2022	BUY	$57.72 - $65.01 $2.35 Million - $2.65 Million	40,800 Added 11.97%	381,553 $23.6 Million
Q1 2022 May 13, 2022	BUY	$57.92 - $72.58 $217,721 - $272,828	3,759 Added 1.12%	340,753 $20.3 Million
Q4 2021 Feb 15, 2022	SELL	$64.88 - $73.64 $1.26 Million - $1.43 Million	-19,400 Reduced 5.44%	336,994 $24.5 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $108,304 - $116,848	-1,600 Reduced 0.45%	356,394 $24.9 Million
Q2 2021 Aug 12, 2021	SELL	$63.47 - $69.35 $1.17 Million - $1.28 Million	-18,500 Reduced 4.91%	357,994 $24.7 Million
Q1 2021 May 17, 2021	SELL	$60.0 - $68.46 $228,000 - $260,147	-3,800 Reduced 1.0%	376,494 $24.3 Million
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $781,770 - $890,790	-13,800 Reduced 3.5%	380,294 $22.2 Million
Q3 2020 Nov 13, 2020	BUY	$62.1 - $78.08 $1.14 Million - $1.43 Million	18,300 Added 4.87%	394,094 $24.9 Million
Q2 2020 Aug 13, 2020	BUY	$72.34 - $84.0 $1.77 Million - $2.06 Million	24,466 Added 6.96%	375,794 $28.9 Million
Q1 2020 May 11, 2020	SELL	$62.63 - $80.22 $688,930 - $882,420	-11,000 Reduced 3.04%	351,328 $26.3 Million
Q4 2019 Feb 10, 2020	SELL	$61.62 - $67.78 $1.22 Million - $1.34 Million	-19,800 Reduced 5.18%	362,328 $23.5 Million
Q3 2019 Oct 31, 2019	SELL	$62.51 - $69.0 $531,335 - $586,500	-8,500 Reduced 2.18%	382,128 $24.2 Million
Q2 2019 Jul 17, 2019	BUY	$61.87 - $69.38 $167,049 - $187,326	2,700 Added 0.7%	390,628 $26.4 Million
Q1 2019 Apr 29, 2019	BUY	$62.53 - $70.05 $4.94 Million - $5.54 Million	79,029 Added 25.58%	387,928 $25.2 Million
Q4 2018 Jan 31, 2019	SELL	$60.54 - $79.0 $2.19 Million - $2.86 Million	-36,200 Reduced 10.49%	308,899 $19.3 Million
Q3 2018 Nov 09, 2018	SELL	$71.28 - $78.92 $1.38 Million - $1.53 Million	-19,403 Reduced 5.32%	345,099 $26.6 Million
Q2 2018 Jul 12, 2018	BUY	$64.88 - $75.68 $129,240 - $150,754	1,992 Added 0.55%	364,502 $25.8 Million
Q1 2018 May 07, 2018	BUY	$72.84 - $88.8 $148,229 - $180,708	2,035 Added 0.56%	362,510 $27.3 Million
Q4 2017 Feb 12, 2018	BUY	$71.15 - $83.52 $3.91 Million - $4.59 Million	54,968 Added 17.99%	360,475 $25.8 Million
Q3 2017 Nov 07, 2017	BUY	$72.11 - $85.47 $289,161 - $342,734	4,010 Added 1.33%	305,507 $24.8 Million
Q2 2017 Aug 08, 2017	BUY	N/A	301,497	301,497 $21.3 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.

Account